CAR-T Cells Can Increase Clinical Remission Rates in Multiple Myeloma PatientsAJMC.com Managed Markets NetworkDisease progression was only found in 1 patient in the very good partial response category. However, 85% of the patients who received CAR-T ce… Continue reading
|
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood …
Markets Insider LONDON, Aug. 2, 2017 /PRNewswire/ — Based on its recent analysis of the blood purification market, Frost & Sullivan recognizes CytoSorbents Corporation with the 2017 Global Frost & Sullivan Award for Product Leadership. CytoSorbents’ deceptively … |
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
Markets Insider … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
Markets Insider … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |
|
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood …
Markets Insider LONDON, Aug. 2, 2017 /PRNewswire/ — Based on its recent analysis of the blood purification market, Frost & Sullivan recognizes CytoSorbents Corporation with the 2017 Global Frost & Sullivan Award for Product Leadership. CytoSorbents’ deceptively … |
Ovarian Cancer News Today |
UC San Diego Team Receives $5.8 Million to Develop Immunotherapy for Ovarian, Other Cancer Patients
Ovarian Cancer News Today Researchers at the University of California San Diego School of Medicine have received a $5.8 million state grant to develop an immunotherapy against hard-to-kill cancer stem cells. The team that won the 30-month grant from the California Institute for … Award-winning Israeli cancer researcher says immunotherapy is the ‘future’ of treatmentJNS.org |